{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:31:00Z","timestamp":1780515060986,"version":"3.54.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clml.2025.08.006","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T10:32:11Z","timestamp":1755253931000},"page":"e1086-e1097","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["It\u2019s \u201cBlin\u201d a Long Time Coming: The Rise of Blinatumomab in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6934-0084","authenticated-orcid":false,"given":"Lauren T.","family":"Shinn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine A.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina S.","family":"Fraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia L.","family":"Benitez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard L.","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Perissinotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.08.006_bib0001","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.4065\/80.11.1517","article-title":"Adult acute lymphoblastic leukemia","volume":"80","author":"Jabbour","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2025.08.006_bib0002","article-title":"SEER cancer statistics review 1975-2018","author":"Howlader","year":"2021","journal-title":"Natl Cancer Institute"},{"key":"10.1016\/j.clml.2025.08.006_bib0003","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ajh.26156","article-title":"Acute lymphoblastic leukemia: a population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017","volume":"96","author":"Sasaki","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.08.006_bib0004","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.08.006_bib0005","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2025.08.006_bib0006","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1182\/blood-2008-11-185132","article-title":"Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)","volume":"113","author":"Bassan","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.08.006_bib0007","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1038\/bcj.2014.48","article-title":"Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia","volume":"4","author":"Bassan","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.08.006_bib0008","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1182\/blood-2014-09-599894","article-title":"Role of allogeneic stem cell transplantation in adult patients with ph-negative acute lymphoblastic leukemia","volume":"125","author":"Dhedin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.08.006_bib0009","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/16078454.2019.1567654","article-title":"Minimal residual disease level predicts outcome in adults with ph-negative B-precursor acute lymphoblastic leukemia","volume":"24","author":"G\u00f6kbuget","year":"2019","journal-title":"Hematol"},{"key":"10.1016\/j.clml.2025.08.006_bib0010","unstructured":"Blincyto. Package insert. Amgen; 2014. Available at: https:\/\/www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-com\/blincyto\/blincyto_pi_hcp_english.pdf. Accessed April 6, 2025."},{"key":"10.1016\/j.clml.2025.08.006_bib0011","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.08.006_bib0012","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.08.006_bib0013","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/Phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.08.006_bib0014","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.08.006_bib0015","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.08.006_bib0016","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of post-reinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2025.08.006_bib0017","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2025.08.006_bib0018","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.08.006_bib0019","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children","volume":"392","author":"Gupta","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.08.006_bib0020","unstructured":"National Comprehensive Cancer Network. Acute lymphoblastic leukemia (Version 3.2024). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/all.pdf (Accessed April 6, 2025)."},{"key":"10.1016\/j.clml.2025.08.006_bib0021","unstructured":"National Comprehensive Cancer Network. Pediatric acute lymphoblastic leukemia (Version 3.2025). https:\/\/www.nccn.org\/professionals\/physicians_gls\/pdf\/ped_all.pdf (Accessed April 6, 2025)."},{"key":"10.1016\/j.clml.2025.08.006_bib0022","first-page":"1","article-title":"Evaluation and management of measurable residual disease in acute lymphoblastic leukemia","volume":"11","author":"Dalle","year":"2020","journal-title":"Ther Adv Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.08.006_bib0023","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1182\/blood-2024-203929","volume":"144","author":"Macaron","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.08.006_bib0024","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1182\/blood-2024-206184","article-title":"Clearance of very low levels of measurable residual disease with blinatumomab significantly improves outcomes in B-cell acute lymphoblastic leukemia","volume":"144","author":"Nguyen","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.08.006_bib0025","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.bbmt.2016.12.639","article-title":"Next-generation sequencing in adult B cell acute lymphoblastic leukemia patients","volume":"23","author":"Sala Torra","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2025.08.006_bib0026","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/bjh.14420","article-title":"Clinical utility of next-generation sequencing-based minimal residual disease in paediatric B-cell acute lymphoblastic leukaemia","volume":"176","author":"Sekiya","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.08.006_bib0027","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/blood-2017-09-806521","article-title":"Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL","volume":"131","author":"Wood","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.08.006_bib0028","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1182\/bloodadvances.2021006727","article-title":"Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods","volume":"6","author":"Kotrov\u00e1","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.08.006_bib0029","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1182\/bloodadvances.2022007378","article-title":"High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse","volume":"6","author":"Short","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.08.006_bib0030","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.3324\/haematol.2021.280078","article-title":"High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL","volume":"107","author":"Cabannes-Hamy","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.08.006_bib0031","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2015-03-633685","article-title":"Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children\u2019s Oncology Group study AALL0232","volume":"126","author":"Borowitz","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.08.006_bib0032","first-page":"1868","article-title":"Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Lymphoid Neoplasia"},{"key":"10.1016\/j.clml.2025.08.006_bib0033","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","article-title":"Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study","volume":"115","author":"Conter","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.08.006_bib0034","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1080\/10428194.2022.2115841","article-title":"Dynamics of minimal residual disease defines a novel risk-classification and the role of allo-HSCT in adult ph-negative B-cell acute lymphoblastic leukemia","volume":"63","author":"Cai","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2025.08.006_bib0035","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified Hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.08.006_bib0036","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","article-title":"Rituximab in B-lineage adult acute lymphoblastic leukemia","volume":"375","author":"Maury","year":"2016","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.08.006_bib0037","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1182\/blood-2018-99-117469","volume":"132","author":"Wieduwilt","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.08.006_bib0038","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALBG 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.08.006_bib0039","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.3324\/haematol.2020.251686","article-title":"Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age of 60 years with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"106","author":"Geyer","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.08.006_bib0040","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.2017.74.3617","article-title":"IKZF1plus defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia","volume":"36","author":"Stanulla","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.08.006_bib0041","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41375-021-01448-2","article-title":"Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study","volume":"36","author":"Moorman","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.08.006_bib0042","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2014-01-547695","article-title":"Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia","volume":"123","author":"Beldjord","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.08.006_bib0043","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/leu.2016.234","article-title":"Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-adapted therapy","volume":"31","author":"Pui","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.08.006_bib0044","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.08.006_bib0045","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-023-01409-5","article-title":"The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades","volume":"16","author":"Jabbour","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2025.08.006_bib0046","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1080\/10428194.2020.1780583","article-title":"Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia","volume":"61","author":"G\u00f6kbuget","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2025.08.006_bib0047","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/ejh.13375","article-title":"Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"104","author":"G\u00f6kbuget","year":"2020","journal-title":"Eur J Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.08.006_bib0048","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1182\/blood-2024-207557","volume":"144","author":"Liedtke","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.08.006_bib0049","doi-asserted-by":"crossref","first-page":"e878","DOI":"10.1016\/S2352-3026(22)00285-X","article-title":"Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia: a single-arm, single-centre phase 2 trial","volume":"9","author":"Jabbour","year":"2022","journal-title":"Lancet Hematol"},{"key":"10.1016\/j.clml.2025.08.006_bib0050","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2014-12-615757","article-title":"IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients","volume":"125","author":"Pulsipher","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.08.006_bib0051","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1182\/bloodadvances.2023009856","article-title":"Next-generation sequencing-based MRD in adults with ALL undergoing hematopoietic cell transplantation","volume":"7","author":"Liang","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.08.006_bib0052","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1200\/JCO.22.02200","article-title":"Children's Oncology Group AALL1331: phase III trial of blinatumomab in children, adolescents, and young adults with low-risk B-cell ALL in first relapse","volume":"41","author":"Hogan","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.08.006_bib0053","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41375-022-01770-3","article-title":"Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL","volume":"37","author":"Locatelli","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.08.006_bib0054","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","article-title":"Blinatumomab added to chemotherapy in infant lymphoblastic leukemia","volume":"388","author":"van der Sluis","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.08.006_bib0055","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2021-149478","article-title":"A phase 3 randomized trial of inotuzumab ozogamicin for newly diagnosed high-risk B-ALL: safety phase results from Children\u2019s Oncology Group Protocol AALL1732","volume":"138","author":"McNeer","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.08.006_bib0056","article-title":"A phase 3 trial of inotuzumab ozogamicin for high-risk B-ALL: second safety phase results from Children\u2019s Oncology Group AALL1732","volume":"41","author":"O\u2019Brien","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.08.006_bib0057","doi-asserted-by":"crossref","first-page":"suppl1","DOI":"10.1182\/hem.V22.1.2025210","article-title":"Blin\u2019-ing is winning for children with B-cell acute lymphoblastic luekemia","volume":"22","author":"Pommert","year":"2025","journal-title":"The Hematologist"},{"key":"10.1016\/j.clml.2025.08.006_bib0058","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1182\/blood-2024-209438","article-title":"Addition of inotuzumab to a pediatric-inspired chemotherapy regimen in young adult patients with B-cell acute lymphoblastic leukemia: findings from the Alliance A041501 phase 3 randomized trial","volume":"144","author":"DeAngelo","year":"2024","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T01:10:30Z","timestamp":1763773830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025002836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":58,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2152265025002836"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.08.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"It\u2019s \u201cBlin\u201d a Long Time Coming: The Rise of Blinatumomab in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}